OncoMatch/Clinical Trials/NCT05613452
Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
Is NCT05613452 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for non-small cell lung cancer.
To investigate the efficacy of carbon ion therapy for stage Ia-IIa primary peripheral non-small cell lung cancer (NSCLC). The primary endpoint was progression-free survival (PFS), and the secondary endpoint was local control rate, overall survival (OS) and toxicities.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage T1-2N0M0, IA, IIA (AJCC/UICC 8th edition)
T1-2N0M0, stage Ia-IIa (AJCC/UICC 8th edition)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
ANC ≥1.5 x 10^9/L, platelet count ≥80 x 10^9/L, hemoglobin ≥9 g/dL
Kidney function
serum creatinine ≤1.5x ULN or CrCl ≥50 ml/min, urinary protein <2+ (if ≥2+, 24-hour urine protein ≤1g)
Liver function
total bilirubin <1.5x ULN, AST/ALT <2x ULN
Cardiac function
no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease or other complications that may affect radiotherapy
Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1>25%, DLCO>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin <1.5 times the upper limit of normal value, and AST, ALT<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary protein <2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05613452 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage T1-2N0M0 or IA or IIA is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages